Saturday 17 October 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.52
0.52
−2.73%
Follow TYRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (45.31%) | (36.87%) | (39.83%) | (34.75%) |
+8 more TTM periods Free account |
|
| (42.15%) | (34.71%) | (37.13%) | (32.73%) | ||
ROIC |
0.00% | (2,173.73%) | (2,614.25%) | (1,409.64%) | |
Return on Tangible Assets |
(43.25%) | (34.82%) | (48.24%) | (41.88%) | |
Free Cash Flow per Share |
(1.67) | (1.66) | (1.60) | (1.53) | |
Free Cash Flow |
(109.90) | (102.47) | (95.28) | (91.20) | |
Capital Expenditures |
(0.25) | (0.21) | (0.14) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(15.53%) | (13.29%) | (18.50%) | (16.42%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.74 | 0.78 | 0.79 | 0.82 | |
Depreciation/Fixed assets |
0.46 | 0.45 | 0.42 | 0.41 | |
Capex/Depreciation |
(0.46) | (0.40) | (0.26) | (0.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.66) | (1.66) | (1.60) | (1.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates